

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-6 (Canceled).

Claim 7 (Currently amended): A method of modifying TALL-104 cells (ATCC CRL 11386) comprising:  
culturing TALL-104 cells in an effective amount of IL-15, wherein said cells grow at a rate faster than when stimulated by IL-2, and have an altered phenotypic, cytotoxic and cytokine profile.

Claim 8 (Original): The method according to claim 7 wherein said modified cells have an increased level of cytotoxicity.

Claim 9 (Original): The method according to claim 7, wherein said modified cells demonstrate a change in a characteristic selected from the group consisting of increased proliferation, differentiation, growth, phenotype, adhesion molecule expression, biodistribution, cytokine production profile, and tumor target spectrum.

Claim 10 (Currently amended): The method according to claim 9 wherein ~~upon stimulation with anti-CD3 antibody~~, said cytokine production profile is characterized by increased expression of IL-10, increased expression of GM-CSF, increased expression of TNF- $\alpha$ , increased expression of TNF- $\beta$ , and decreased expression of gamma interferon upon stimulation with anti-CD3 antibody.

Claim 11 (Canceled).

Claim 12 (Previously presented): The method according to claim 9 wherein said phenotype is characterized by increased expression of the cytotoxic adhesion/activation marker CD56 and decreased expression of the adhesion molecule CD38.

Claims 13-21 (Canceled).